Join Cognition Therapeutics for an investor webcast to review topline results from the Phase 2 study of CT1812 in patients with dementia with Lewy bodies (DLB). The event will feature a discussion with James E. Galvin, M.D., M.P.H., founding director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine and principal investigator in the SHIMMER study. A live question and answer session will follow formal presentations.